Reshma Kewalramani, Vertex CEO (Barry Chin/The Boston Globe via Getty Images)
FDA approves Vertex and CRISPR's Casgevy as first CRISPR-edited therapy for beta-thalassemia
The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy to treat beta-thalassemia, Vertex said Tuesday, making it the first-ever CRISPR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.